179 related articles for article (PubMed ID: 25734548)
1. Development and Validation of an Immuno-PET Tracer as a Companion Diagnostic Agent for Antibody-Drug Conjugate Therapy to Target the CA6 Epitope.
Ilovich O; Natarajan A; Hori S; Sathirachinda A; Kimura R; Srinivasan A; Gebauer M; Kruip J; Focken I; Lange C; Carrez C; Sassoon I; Blanc V; Sarkar SK; Gambhir SS
Radiology; 2015 Jul; 276(1):191-8. PubMed ID: 25734548
[TBL] [Abstract][Full Text] [Related]
2. Two Patient Studies of a Companion Diagnostic Immuno-Positron Emission Tomography (PET) Tracer for Measuring Human CA6 Expression in Cancer for Antibody Drug Conjugate (ADC) Therapy.
Natarajan A; Srinivas SM; Azevedo C; Greene L; Bauchet AL; Jouannot E; Lacoste-Bourgeacq AS; Guizon I; Cohen P; Naneix AL; Ilovich O; Cisneros J; Rupanarayan K; Chin FT; Iagaru A; Dirbas FM; Karam A; Gambhir SS
Mol Imaging; 2020; 19():1536012120939398. PubMed ID: 33104454
[TBL] [Abstract][Full Text] [Related]
3. MicroPET/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-scid mice using (64)Cu-NOTA-panitumumab F(ab')2 fragments.
Boyle AJ; Cao PJ; Hedley DW; Sidhu SS; Winnik MA; Reilly RM
Nucl Med Biol; 2015 Feb; 42(2):71-7. PubMed ID: 25456837
[TBL] [Abstract][Full Text] [Related]
4. ImmunoPET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer with a Dual-Labeled Bispecific Antibody Fragment.
Luo H; England CG; Goel S; Graves SA; Ai F; Liu B; Theuer CP; Wong HC; Nickles RJ; Cai W
Mol Pharm; 2017 May; 14(5):1646-1655. PubMed ID: 28292180
[TBL] [Abstract][Full Text] [Related]
5. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen.
Elsässer-Beile U; Reischl G; Wiehr S; Bühler P; Wolf P; Alt K; Shively J; Judenhofer MS; Machulla HJ; Pichler BJ
J Nucl Med; 2009 Apr; 50(4):606-11. PubMed ID: 19289418
[TBL] [Abstract][Full Text] [Related]
6. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
7. PET imaging of CD105/endoglin expression with a ⁶¹/⁶⁴Cu-labeled Fab antibody fragment.
Zhang Y; Hong H; Orbay H; Valdovinos HF; Nayak TR; Theuer CP; Barnhart TE; Cai W
Eur J Nucl Med Mol Imaging; 2013 May; 40(5):759-67. PubMed ID: 23344138
[TBL] [Abstract][Full Text] [Related]
8. In vivo evaluation of 177Lu- and 67/64Cu-labeled recombinant fragments of antibody chCE7 for radioimmunotherapy and PET imaging of L1-CAM-positive tumors.
Grünberg J; Novak-Hofer I; Honer M; Zimmermann K; Knogler K; Bläuenstein P; Ametamey S; Maecke HR; Schubiger PA
Clin Cancer Res; 2005 Jul; 11(14):5112-20. PubMed ID: 16033825
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and PET imaging properties of two recombinant anti-PSMA antibody fragments in comparison to their parental antibody.
Wiehr S; Bühler P; Gierschner D; Wolf P; Rolle AM; Kesenheimer C; Pichler BJ; Elsässer-Beile U
Prostate; 2014 May; 74(7):743-55. PubMed ID: 24610028
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography imaging of CD105 expression during tumor angiogenesis.
Hong H; Yang Y; Zhang Y; Engle JW; Barnhart TE; Nickles RJ; Leigh BR; Cai W
Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1335-43. PubMed ID: 21373764
[TBL] [Abstract][Full Text] [Related]
11. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
[TBL] [Abstract][Full Text] [Related]
12. ⁸⁹Zr-Labeled Versus ¹²⁴I-Labeled αHER2 Fab with Optimized Plasma Half-Life for High-Contrast Tumor Imaging In Vivo.
Mendler CT; Gehring T; Wester HJ; Schwaiger M; Skerra A
J Nucl Med; 2015 Jul; 56(7):1112-8. PubMed ID: 25999431
[TBL] [Abstract][Full Text] [Related]
13. Development of a Chimeric Antigen-Binding Fragment Directed Against Human Galectin-3 and Validation as an Immuno-Positron Emission Tomography Tracer for the Sensitive
Peplau E; De Rose F; Reder S; Mittelhäuser M; Scafetta G; Schwaiger M; Weber WA; Bartolazzi A; Skerra A; D'Alessandria C
Thyroid; 2020 Sep; 30(9):1314-1326. PubMed ID: 32200708
[No Abstract] [Full Text] [Related]
14. PET Imaging of Abdominal Aortic Aneurysm with 64Cu-Labeled Anti-CD105 Antibody Fab Fragment.
Shi S; Orbay H; Yang Y; Graves SA; Nayak TR; Hong H; Hernandez R; Luo H; Goel S; Theuer CP; Nickles RJ; Cai W
J Nucl Med; 2015 Jun; 56(6):927-32. PubMed ID: 25883125
[TBL] [Abstract][Full Text] [Related]
15. Site-Specific Immuno-PET Tracer to Image PD-L1.
Wissler HL; Ehlerding EB; Lyu Z; Zhao Y; Zhang S; Eshraghi A; Buuh ZY; McGuth JC; Guan Y; Engle JW; Bartlett SJ; Voelz VA; Cai W; Wang RE
Mol Pharm; 2019 May; 16(5):2028-2036. PubMed ID: 30875232
[TBL] [Abstract][Full Text] [Related]
16. High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation.
Mendler CT; Friedrich L; Laitinen I; Schlapschy M; Schwaiger M; Wester HJ; Skerra A
MAbs; 2015; 7(1):96-109. PubMed ID: 25484039
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of two novel ⁶⁴Cu-labeled RGD peptide radiotracers for enhanced PET imaging of tumor integrin αvβ₃.
Hernandez R; Czerwinski A; Chakravarty R; Graves SA; Yang Y; England CG; Nickles RJ; Valenzuela F; Cai W
Eur J Nucl Med Mol Imaging; 2015 Nov; 42(12):1859-68. PubMed ID: 26016906
[TBL] [Abstract][Full Text] [Related]
18. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.
Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ
J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420
[TBL] [Abstract][Full Text] [Related]
19. 64Cu-p-NH2-Bn-DOTA-hu14.18K322A, a PET radiotracer targeting neuroblastoma and melanoma.
Vavere AL; Butch ER; Dearling JL; Packard AB; Navid F; Shulkin BL; Barfield RC; Snyder SE
J Nucl Med; 2012 Nov; 53(11):1772-8. PubMed ID: 23064212
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu-labeled bevacizumab in colorectal cancer xenografts.
Paudyal B; Paudyal P; Oriuchi N; Hanaoka H; Tominaga H; Endo K
Cancer Sci; 2011 Jan; 102(1):117-21. PubMed ID: 21070475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
